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Abstract  Visceral  angioedema  is a  rare  complication  of  therapy  with  angiotensin-converting
enzyme  (ACE)  inhibitors.  Clinical  presentation  includes  nausea,  vomiting,  abdominal  pain  and
diarrhea. Early  detection  of this  entity  can  prevent  recurrent  episodes  and  unnecessary  invasive
procedures,  including  surgery.
This article  describes  a 46-year-old-woman  who  presented  to  the  emergency  department  with
abdominal pain,  associated  with  nausea  and  vomiting.  She had  been  taking  ramipril  for  15  days.
A computed  tomography  was  performed  which  revealed  thickening  of  a  jejunal  segment,  with
submucosal edema.
ACE  inhibitor-associated  angioedema  was  suspected  and  the  medication  was  discontinued,  with
resolution of  symptoms  in  48  h.
After  7 months  of  follow-up,  the  patient  is  asymptomatic.
Despite  of  its  rarity,  ACE  inhibitor-induced  small-bowel  angioedema  should  be  included  in  the
differential  diagnosis  when  patients  receiving  ACE inhibitor  therapy  present  with  abdominal
complaints.
© 2015  Sociedade  Portuguesa  de Gastrenterologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is
an open  access  article  under  the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Resumo  O  angioedema  visceral  é uma  complicac¸ão  rara  da  terapêutica  com  inibidores  da
enzima de  conversão  da  angiotensina  (IECA).
O quadro  clínico  inclui  náuseas,  vómitos,  dor  abdominal  e diarreia.
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O  reconhecimento  precoce  desta  entidade  pode  evitar  episódios  recorrentes  e  procedimentos
invasivos  desnecessários,  incluindo  cirurgia.
Descrevemos  o  caso  clínico  de  uma  mulher  de 46  anos,  que  recorreu  ao  servic¸o  de urgência  por
dor abdominal,  acompanhada  de náuseas  e vómitos.  Estava  medicada  desde  há quinze  dias  com
ramipril.
A tomografia  computorizada  identificou  espessamento  parietal  de  um  segmento  jejunal,  com
edema submucoso.
Foi colocada  a  hipótese  diagnóstica  de  angioedema  visceral  induzido  por  IECA.
Suspendeu-se  a  terapêutica  com  ramipril,  com  remissão  completa  da  sintomatologia  em
48 horas.
Após  7  meses  de  follow-up,  encontra-se  assintomática.
Apesar da  sua  raridade,  o  angioedema  visceral  induzido  por  IECA  deve  ser  incluído  no diagnóstico
diferencial  de  dor  abdominal  nos  doentes  medicados  com  IECA.
©  2015  Sociedade  Portuguesa  de Gastrenterologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este
e´ um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
1. Case  report
A  46-year-old-woman  presented  to  the emergency  depart-
ment  with  a  one-day  crampy  abdominal  pain,  associated
with  nausea  and vomiting.  The  patient’s  past  medical  his-
tory  was  relevant  for hypertension,  for  which  she  was  taking
ramipril  for  15  days.
She  denied  additional  medication  besides  ramipril.  She
also  denied  smoking.  She  had  no  known  allergies  to  drugs  or
environmental  agents,  and  her  travel  history  was  negative.
There  was no  family  history  for  any  diseases.
On  physical  examination,  she  was  afebrile,  with  a heart
rate  of  67  beats  per  minute  and  a  blood  pressure  of
123/76  mmHg.  She  had  no  stridor  or  facial  swelling.  Breath
sounds  were  normal.  Abdominal  exam  disclosed  tenderness
in  the  periumbilical  area.
Laboratory  investigations  revealed  a white  blood  cell
count  of  11.100  microliter  (L) (9.400  neutrophils/L;
100  eosinophils/L;  1.400  lymphocytes/L)  and C-reactive
protein  of  2.5  miligrams/deciliter  (mg/dL)  (normal
value  <  0.3  mg/dL);  serum  electrolytes,  liver  enzymes,
serum  amylase  and  renal  function  tests  were  in the normal
range.  Serologies  for  celiac  disease  and Crohn’s  disease
were  negative.
Chest  X-ray  did not  reveal  any  changes  and upright
abdominal  X-ray  revealed  air-fluid  levels.
An  abdominal  computed  tomography  (CT)  was  performed
which  revealed  thickening  of  a jejunal  segment,  with  sub-
mucosal  edema  giving  a  ‘‘target-sign’’  appearance.  There
was  also  moderate  ascites  (Fig.  1).
Push  enteroscopy  was  performed  3  days  after  onset  of
symptoms  and  did  not  reveal  any  changes  (the  estimated
depth  of  insertion  was  proximal  jejunum).  Biopsies  were
performed  which  revealed  normal  results.
She  was  diagnosed  with  visceral  angioedema  secondary
to  angiotensin-converting  enzyme  (ACE)  inhibitor  therapy.
Ramipril  was  discontinued,  and  symptoms  resolved  com-
pletely  in  48  h. Upright  abdominal  X-ray  was  repeated  and
did  not  reveal  air-fluid  levels.
She  was  discharged  home  after  6  days  on calcium  channel
blocker.
After  7 months  of  follow-up,  the  patient  is  asymptomatic.
2. Discussion
Angiotensin-converting  enzyme  (ACE)  inhibitors  have
achieved  widespread  usage in the  treatment  of  cardiovas-
cular  and  renal  disease;  they  have  proved  effectiveness  in
the  treatment  of  hypertension,  they  decrease  mortality  in
congestive  heart  failure  and  left ventricular  dysfunction
after  myocardial  infarction  and  they  delay  the  progression
of  diabetic  nephropathy.1
The  most  common  adverse  reactions  are cough  and  skin
rash.2 Peripheral  angioedema  has been  reported  in  0.1--0.2%
of  patients,  and  visceral  angioedema  has  been  reported  to
occur  even  less  commonly.3--6
These  drugs  inhibit  competitively  the activity  of  ACE  to
prevent  formation  of  angiotensin  II  from  angiotensin  I. Inhi-
bition  of  this  enzyme  also  leads  to  accumulation  of  kinins
including  bradykinin.1
Visceral  angioedema  pathogenesis  is  not  clear.  The
most  plausible  mechanism  is  an increase  in the levels  of
bradykinin  and  its  metabolite.7 Bradykinin  increases  vascu-
lar  permeability1 and  promotes  vasodilation4,8,9 by  stimulat-
ing  the production  of  arachidonic  acid  metabolites,  nitric
oxide,  and  endothelium-derived  hyperpolarizing  factor  in
vascular  endothelium,  thereby  leading  to  angioedema.10
In fact,  during  an acute  attack  of  angioedema  secondary
to ACE inhibition,  the bradykinin  concentration  can  increase
to  more  than  10  times  the normal level9 and  fall to  normal
levels  during remission  after  withdrawal  of  the drug.11
ACE-inhibitor-induced  angioedema  of the intestine  is
more  common  in women12 in the fifth  decade  of life.11,13
Clinical  presentation  includes  nausea,  vomiting,  abdom-
inal  pain  and  diarrhea.14--17 Symptoms  typically  present
within  24--48  h  after  initiation  of  ACE inhibitor,18 but  there
are  case  reports  between  2  weeks  and  18  months  after
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Figure  1  Abdominal  computed  tomography  with  oral  and
intravenous  contrast  revealing  thickening  of  a  jejunal  segment,
with submucosal  edema  (arrows)  giving  a  so-called  ‘‘target-
sign’’ appearance  (images  a and  b).  Image  (c)  shows  moderate
ascites (arrow).
initiation  of  therapy13 and there  is  one  case  report  9  years
after  initiation  of  therapy.6
Although  the  CT  features  are not  pathognomonic,  they
provide  valuable  clues  to  the diagnosis;  a  previous  case
series  suggested  CT findings  of  ascites,  small  bowel  wall
thickening,  dilation  without  obstruction,  and  straightening
should  prompt  inclusion  of  the  diagnosis  in the differential
while  taking  an  ACE-inhibitors.19
Inflammatory  bowel disease,  infection,  vasculitis,
ischemic  bowel  and mechanical  obstruction  all  need  to  be
considered  in the differential.20,21
Supportive  care  and cessation  of ACE-inhibitor  usage  are
the  cornerstones  of  treatment.17 Symptoms  usually  resolve
within  48  h13,20,22,23 as  illustrated  by  the presented  case.
Nevertheless,  in a  previous  study,11 a median  of  10  months
(range  from  1  day  to 10  years)  elapsed  between  the  onset  of
angioedema  and  withdrawal  of the ACE  inhibitor.  In  the  pre-
sented  case,  due  to  the  prompt  diagnosis,  ramipril  therapy
was  withdrawn  in the same  day as  angioedema  presentation.
Recurrent  angioedema  has  been  reported  to occur  in
1.5--10%  of patients  after changing  from  ACE-inhibitor  to
angiotensin  II  receptor  blockers.  However,  it is  believed  that
this  may  actually  represent  residual  effects  of  ACE-inhibitor
angioedema.24
It is  important  to  recognize  this  entity  as  many  of  the
patients  discussed  in the  literature  underwent  unnecessary
invasive procedures  such  as  exploratory  laparotomy,  intesti-
nal  biopsy  and  resection.16,18,20,21
In  conclusion,  ACE  inhibitors-induced  small-bowel
angioedema  should  be included  in  the  differential  diagnosis
in  any  patient  with  unexplained  abdominal  pain  while  on
ACE  inhibitors.16,18
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